Perspective: How I See the Future for TAVR in Younger Patients With Bicuspid AS
Presenter:
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - Abbott; Abiomed; Amgen; AstraZenca; Bayer AG; Bbraun; Biotronik; Boehringer Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; Cardinal Health; CardioValve; Cordis Medical; Corflow Therapeutics; CSL Behring; Daiichi-Sankyo/Elil Lilly and Company; Edwards Lifesciences; Farapulse Inc.; Fumedica; Guerbet; Idorsia; Inari Medical; InfraredX; Janssen Pharmaceuticals; Cordis Corporation, a Johnson & Johnson company; Medalliance; Medicure; Medtronic; Merck Sharp & Dohm; Miracor Medical; Novartis; NovoNordisk; Organon; OrPha Suisse; Pharming Tech; Pfizer; Polares; Regeneron; Sanofi-Aventis; Servier; Sinomed; Terumo Medical Corporation; Vifor; V-Wave
Video Player is loading.